Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants

    December 2021 in “ Frontiers in Medicine ”
    Chutima Seree-aphinan, Kumutnart Chanprapaph, Ploysyne Rattanakaemakorn, Chavachol Setthaudom, Thanitta Suangtamai, Cherrin Pomsoong, Yanisa Ratanapokasatit, Poonkiat Suchonwanit
    Image of study
    TLDR Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
    The study conducted on 32 dermatological patients found that the Sinovac-CoronaVac COVID-19 vaccine induced a lower humoral immune response in patients receiving certain systemic immunosuppressive therapies compared to those who did not. All participants developed anti-SARS-CoV-2 IgG antibodies, but those on certain immunosuppressants had lower neutralizing antibody levels and seroconversion rates. However, patients on low-dose methotrexate, low-dose systemic corticosteroids, or biologics showed a better immune response. The study suggests that the type of immunosuppressive therapy and the patient's comorbidities influence the immune response to the vaccine. No participants developed symptomatic COVID-19 during a 3-month follow-up. The study did not assess the cellular immune response and had a small sample size, indicating the need for further research.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 35 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Verteporfin and Microneedling

      in Treatments 5 months ago
      Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Similar Research

    5 / 1000+ results